Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FJ-PAML-26 for newly diagnosed pediatric acute myeloid leukemia
ChiCTR2600132177Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Complete remission rate and measurable residual disease negativity rate after 2 induction courses. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600132177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132177.